Hangzhou Sumgen Biotech Co., Ltd.
Clinical trials sponsored by Hangzhou Sumgen Biotech Co., Ltd., explained in plain language.
-
New cancer drug SG2918 enters first human tests
Disease control OngoingThis early-stage trial tests an experimental drug called SG2918 in 17 people with advanced cancers that no longer respond to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive the drug by IV every three w…
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug SG301 tested in blood cancer patients who have run out of options
Disease control OngoingThis early-stage trial is testing a new drug called SG301 in about 61 people with blood cancers like multiple myeloma that have returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose to use in future studies. Researche…
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug SG1827 enters first human tests for Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC